Literature DB >> 12801370

Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery.

I B Gosbell1, V Toumasatos, J Yong, R S Kuo, D H Ellis, R C Perrie.   

Abstract

Scedosporium prolificans infections of normal hosts usually require extensive debridement and sometimes amputation to effect cure, due to the intrinsic resistance of this species to available antifungal agents. Newer agents have not tested favourably. Variable results are obtained with voriconazole, and 100% resistance is described with echinocandins. Itraconazole and terbinafine has offered synergy against various moulds including S. prolificans. In vivo success is reported with the azole/terbinafine combination in S. apiospermum pulmonary infection and Pythium insidiosum periorbital cellulitis. We report a case of orthopaedic infection in a non-immunocompromised host with S. prolificans, in which the combinations of itraconazole/terbinafine and voriconazole/terbinafine showed synergy in vitro, and success was achieved without radical surgery, using voriconazole and terbinafine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12801370     DOI: 10.1046/j.1439-0507.2003.00878.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  23 in total

Review 1.  [Strategies for antifungal treatment failure in intensive care units].

Authors:  C Arens; M Bernhard; C Koch; A Heininger; D Störzinger; T Hoppe-Tichy; M Hecker; B Grabein; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2015-09       Impact factor: 1.041

2.  Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.

Authors:  Michael J Dolton; Vidya Perera; Lisa G Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

3.  Infective endocarditis caused by Scedosporium prolificans infection in a patient with acute myeloid leukemia undergoing induction chemotherapy.

Authors:  Yotaro Ochi; Nobuhiro Hiramoto; Hiroshi Takegawa; Noboru Yonetani; Asako Doi; Chihiro Ichikawa; Yukihiro Imai; Takayuki Ishikawa
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

4.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

Review 5.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Scedosporium apiospermum brain abscesses in an immunocompetent man with silicosis.

Authors:  Heather L Wilson; Karina J Kennedy
Journal:  Med Mycol Case Rep       Date:  2013-03-01

7.  Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma.

Authors:  Natasha E Holmes; Janine M Trevillyan; Sarah E Kidd; Trishe Y-M Leong
Journal:  Med Mycol Case Rep       Date:  2013-04-19

Review 8.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

9.  In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Monia Maracci; Annette W Fothergill; Isabella Baldassarri; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.